MS-275

• Background:

  MS 275, also referred to as Entinostat, is a benzamide histone deacetylase inhibitor. It preferentially inhibits HDAC1 and HDAC3. It is currently undergoing several clinical trials for the treatment of Hodgkin's lymphoma, advanced breast cancer, and for metastatic lung cancer.

• Description:

  HDAC inhibitor

• Product Name Alternative:

  3-pyridinylmethyl [[4-[[ (2-aminophenyl) amino]carbonyl]phenyl]methyl]carbamate, N- (2-Aminophenyl) -4-[N- (pyridine-3ylmethoxycarbonyl) aminomethyl]benzamide

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cell Signaling | Epigenetics and Nuclear Signaling | Cancer

• Purity:

  >98.5

• Weight:

  0.001

• Format:

  Off white solid

• Solubility:

  Soluble in DMSO or methanol.

• Molecular Formula:

  C21H20N4O3

• Molecular Weight:

  376.41

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Camphausen K., Burgan W., Cerra M., Oswald K.A., Trepel J.B., Lee M.J., et al. (2004) Cancer Res. 316-21.

• CAS Number:

  209783-80-2